Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 9, 1299
eCollection

Adverse Effects of Immunoglobulin Therapy

Affiliations
Review

Adverse Effects of Immunoglobulin Therapy

Yi Guo et al. Front Immunol.

Abstract

Immunoglobulin has been widely used in a variety of diseases, including primary and secondary immunodeficiency diseases, neuromuscular diseases, and Kawasaki disease. Although a large number of clinical trials have demonstrated that immunoglobulin is effective and well tolerated, various adverse effects have been reported. The majority of these events, such as flushing, headache, malaise, fever, chills, fatigue and lethargy, are transient and mild. However, some rare side effects, including renal impairment, thrombosis, arrhythmia, aseptic meningitis, hemolytic anemia, and transfusion-related acute lung injury (TRALI), are serious. These adverse effects are associated with specific immunoglobulin preparations and individual differences. Performing an early assessment of risk factors, infusing at a slow rate, premedicating, and switching from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG) can minimize these adverse effects. Adverse effects are rarely disabling or fatal, treatment mainly involves supportive measures, and the majority of affected patients have a good prognosis.

Keywords: adverse effects; immunoglobulin; premedication; preventive measures; risk factors.

Figures

Figure 1
Figure 1
Process that minimizes or prevents immunoglobulin-associated adverse reactions.

Similar articles

See all similar articles

Cited by 9 PubMed Central articles

See all "Cited by" articles

References

    1. Barahona Afonso AF, Joao CM. The production processes and biological effects of intravenous immunoglobulin. Biomolecules (2016) 6(1):15.10.3390/biom6010015 - DOI - PMC - PubMed
    1. Pecoraro A, Crescenzi L, Granata F, Genovese A, Spadaro G. Immunoglobulin replacement therapy in primary and secondary antibody deficiency: the correct clinical approach. Int Immunopharmacol (2017) 52:136–42.10.1016/j.intimp.2017.09.005 - DOI - PubMed
    1. Qin YH, Zhou TB, Su LN, Lei FY, Zhao YJ, Huang WF. The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a meta-analysis of 13 randomized controlled trials. Blood Coagul Fibrinolysis (2010) 21(8):713–21.10.1097/MBC.0b013e3283401490 - DOI - PubMed
    1. Chen S, Dong Y, Yin Y, Krucoff MW. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart (2013) 99(2):76–82.10.1136/heartjnl-2012-302126 - DOI - PubMed
    1. Oaklander AL, Lunn MP, Hughes RA, van Schaik IN, Frost C, Chalk CH. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. Cochrane Database Syst Rev (2017) 1:Cd010369.10.1002/14651858.CD010369.pub2 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Feedback